Sign in
Trending NewsTrending News

AstraZeneca puts Covid-19 vaccine trial on hold over safety concern: Report

The study is testing a Covid-19 vaccine being developed by AstraZeneca and University of Oxford researchers at various sites, including the United Kingdom, where the adverse event was reported.

Updated on: Sep 9, 2020, 05:11:36 IST
As Prefered on
Share via
  • facebook
  • twitter
  • linkedin
Copy link
  • copy link

AstraZeneca Plc has paused a late-stage trial of one of the leading Covid-19 vaccine candidates after a suspected serious adverse reaction in a study participant, health news website Stat News reported on Tuesday.

The nature of the case and when it happened were not detailed, although the participant is expected to recover, according to Stat News. (Reuters)
The nature of the case and when it happened were not detailed, although the participant is expected to recover, according to Stat News. (Reuters)

It quoted an AstraZeneca spokesperson as saying in a statement that the “standard review process triggered a pause to vaccination to allow review of safety data.”

The study is testing a Covid-19 vaccine being developed by AstraZeneca and University of Oxford researchers at various sites, including the United Kingdom, where the adverse event was reported.

The nature of the case and when it happened were not detailed, although the participant is expected to recover, according to Stat News.

The suspension of the trial has impacted other AstraZeneca vaccine trials - as well as clinical trials being conducted by other vaccine makers, which are looking for signs of similar reactions, Stat said.

The AstraZeneca spokesperson’s statement said that “in large trials, illnesses will happen by chance but must be independently reviewed to check this carefully.” Stat reported that serious adverse reactions vary and can include issues that require hospitalization, life-threatening illness and death.

AstraZeneca did not immediately respond to a request for comment.

Nine leading U.S. and European vaccine developers pledged on Tuesday to uphold scientific safety and efficacy standards for their experimental vaccines despite the urgency to contain the coronavirus pandemic.

The companies, including AstraZeneca, Pfizer Inc and GlaxoSmithKline, issued what they called a “historic pledge” after a rise in concern that safety standards might slip in the face of political pressure to rush out a vaccine.

The companies said they would “uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first Covid-19 vaccines.”

The other signatories were Johnson & Johnson, Merck & Co, Moderna Inc, Novavax Inc, Sanofi and BioNTech.

ABOUT THE AUTHOR

Follow the latest breaking news, major developments and agenda-setting stories from India and around the world with the newsdesk at Hindustan Times. Operating round the clock, the desk brings together experienced editors, reporters and correspondents to deliver fast, accurate and contextual reporting across subjects that influence public policy, governance, business, society and international affairs. The HT News Desk covers politics, elections, government policies, the economy, business and markets, science and technology, the environment, law and order, infrastructure, education, climate issues and geopolitics, while closely tracking developments across states, institutions and global capitals. The team also leads coverage of major breaking news events, policy announcements, court proceedings, natural disasters, public emergencies and significant international developments. Reports published by the newsdesk are based on information gathered from reporters on the ground, official statements, government agencies, court records, regulatory filings, recognised institutions and other authoritative sources. Stories undergo editorial scrutiny and verification processes to ensure accuracy, fairness and relevance, and are updated as events evolve and additional information becomes available. Whether covering a key political decision in New Delhi, an economic policy shift affecting millions, a landmark court ruling or a major global event, the HT News Desk aims to provide readers with reliable, fact-based journalism that delivers not only the latest developments but also the context and analysis needed to understand their wider implications.